Stereotactic Body Radiotherapy Viable Alternative for Localized Prostate Cancer
Findings show equivalent efficacy to moderately fractionated radiotherapy with enhanced convenience
Tenecteplase Has Similar Safety to TPA for Acute Ischemic Stroke
TNK associated with higher likelihood of excellent functional outcome and reduced disability at three months
IOTA ADNEX at 10 Percent Has Higher Sensitivity for Ovarian Cancer
Sensitivity higher, but some loss seen in specificity, when compared with Risk of Malignancy 1 index at threshold of 250
Radon Exposure Tied to Higher Risk for Childhood Leukemia
Findings seen even for exposure below the U.S. Environmental Protection Agency guidelines
FDA Approves Itovebi for Locally Advanced, Metastatic Breast Cancer
Approval is for endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative disease
Progression-Free Survival Improved With Nivolumab + AVD in Hodgkin Lymphoma
Longer progression-free survival seen with nivolumab + doxorubicin, vinblastine, and dacarbazine (AVD) versus brentuximab vedotin + AVD
FDA Approves Hympavzi for Hemophilia
Approval is for prophylactic treatment and targets protein in the blood clotting process
2008 to 2022 Saw Rise in Industry-Sponsored Adult Cancer Clinical Trials
From 2018 to 2022, industry-to-federally sponsored trial ratio was 8.1
Guidelines Developed for EBUS-TBNA Specimen Processing, Handling
Nine statements developed, including performing four or more versus three or fewer needle passes in suspected malignant disease
Liberal Transfusion Strategy May Avert Unfavorable Neurological Outcome
Fewer patients with acute brain injury receiving transfusion triggered by hemoglobin <9 g/dL versus <7 g/dL had unfavorable neurological outcome
